The comparison of remimazolam and midazolam in bronchoscopic sedation: a systematic review and meta-analysis of randomized controlled trials
Files
Date
2025-07-08
Authors
Yahya Kayed AbuJwaid
Salahaldeen Deeb
Alhareth M. Amro
Yousef Abu Asbeh
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Media SA (Switzerland)
Abstract
Remimazolam is a novel ultra-short-acting benzodiazepine that has shown promise as a sedative agent for bronchoscopy. This systematic review and meta-analysis evaluated the efficacy and safety of remimazolam compared with midazolam in bronchoscopy sedation. Four randomized controlled trials involving 630 patients were included. Remimazolam significantly reduced induction time and recovery time and decreased the need for rescue sedation compared with midazolam, without affecting bronchoscopy duration or increasing intraoperative or postoperative complications. However, high heterogeneity and the limited number of studies require cautious interpretation. Further high-quality randomized trials are recommended to confirm these findings.
Description
This systematic review and meta-analysis compares remimazolam and midazolam for bronchoscopy sedation, demonstrating that remimazolam provides faster induction and recovery with reduced need for rescue sedation while maintaining a comparable safety profile. The study supports remimazolam as a promising alternative sedative in bronchoscopy and highlights the need for further large-scale randomized trials.
Keywords
Citation
AbuJwaid YK, Deeb S, Amro AM, Abu Asbeh Y. The comparison of remimazolam and midazolam in bronchoscopic sedation: a systematic review and meta-analysis of randomized controlled trials. Front Med. 2025;12:1581280. doi:10.3389/fmed.2025.1581280.